AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04410991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolebrutinib
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Study NCT04410991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriflunomide HMR1726
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Study NCT04410991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match Tolebrutinib
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Study NCT04410991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match Teriflunomide
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Study NCT03341689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Psilocybin
Description: 0.0143 mg/kg psilocybin capsule
Study NCT03341689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: microcrystalline cellulose capsule
Study NCT01668901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: anticoagulation
Study NCT01668901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: antiplatelet
Study NCT02762149 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve stimulator
Description: The nerve stimulator (Stimpod NMS 450: Xavant technology (PTY) Ltd; Pretoria, South Africa or similar nerve stimulator) will be connected to the epidural catheter through an adapter (Johans ECG Adapter, Arrow International Inc., Reading). The epidural catheter and the adapter will be primed with a standard volume of 3 ml of sterile normal saline to allow for effective electrical conduction. Secured connections and avoidance of any air within in the system must be ensured to avoid high impedance in the circuit, which could result in false negatives. The cathode terminal of the stimulator will then be attached to the metal hub of the adapter and the anode terminal will be connected to the electrode placed over the deltoid muscle.
Study NCT03107832 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural anesthesia procedure
Description: general anesthesia procedure
Study NCT03107832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracic epidural anesthesia procedure
Description: general anesthesia procedure
Study NCT02547259 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: pain words test
Description: words to painful sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer will need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the D key on the keyboard if they feel that they have not learned this word.
Study NCT02547259 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pain words test
Description: words to painful sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer will need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the D key on the keyboard if they feel that they have not learned this word.
Study NCT02547259 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: negative words test
Description: words to negative sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the D key on the keyboard if they feel that they have not learned this word.
Study NCT02547259 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: negative words test
Description: words to negative sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the D key on the keyboard if they feel that they have not learned this word.
Study NCT02374671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VisAbility Micro Insert
Description: Subjects are implanted with the VisAbility Micro Insert (Model SGP-046) and followed for 24 months.
Study NCT03581825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A Multifocal
Description: JJVC Investigational Multifocal Contact Lens
Study NCT03581825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A Sphere
Description: ACUVUE OASYS 2-WEEK with HYDRACLEAR PLUS
Study NCT03581825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Multifocal
Description: 1-Day Acuvue Moist Brand Multifocal Contact Lens
Study NCT03581825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Sphere
Description: 1-Day Acuvue Moist Brand Contact Lens
Study NCT02508246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT02508246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT02508246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02508246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02508246 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT02508246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WEE1 Inhibitor AZD1775
Description: Given PO
Study NCT03217682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Music therapy sessions
Study NCT03217682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage Therapy
Description: Massage therapy sessions
Study NCT03599973 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Plasmalyte A Viaflo
Description: Fluid therapy to be given according to the principle of 4-2-1 (4 ml of crystalloid fluid for each of the first 10 kg of weight (0-10 kg), 2 ml of crystalloid fluid for each of the second 10 kg of weight (11-20 kg) and 1 ml of crystalloid fluid for each kg of weight over 20.
Study NCT01688687 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic submucosal dissection
Study NCT00415077 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRK
Description: PRK
Study NCT00415077 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MMC PRK
Description: mitomycin C PRK
Study NCT00415077 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASEK
Description: LASEK
Study NCT04041011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.Experimental: A (Part 1): Fluzoparib and SHR -1316
Description: 1．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
Study NCT04041011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.Experimental: B (Part 1): Fluzoparib and SHR -1316
Description: 2．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
Study NCT04041011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion
Description: 3．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
Study NCT01993173 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap (ADACEL)
Description: 0.5 mL, Intramuscular
Study NCT01993173 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DT vaccine (Diphtheria and Tetanus Combined Vaccine, Adsorbed)
Description: 0.5 mL, Intramuscular
Study NCT01993173 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Td vaccine (Diphtheria and Tetanus Combined Vaccine for Adults and Adolescents, Adsorbed)
Description: 0.5 mL, Intramuscular
Study NCT03715179 — intervention group
Intervention type: DEVICE
Intervention: Ostomy Pouching System
Description: An ostomy pouching system is a medical device that provides a means for the collection of effluent from a surgically diverted biological system (colon, ileum, bladder), specifically from a stoma. No intervention is administered during the course of this study.
Study NCT03510585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saline and sniffing
Description: This technique is a combination of positioning (laying down), saline instilation (5 ml in each side), sniffing (the side that received saline instilation) and throat vibration. Then the other side.
Study NCT03510585 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sniffing
Description: This technique is a combination of positioning (laying down), sniffing (the side that received saline instilation) and throat vibration. Then the other side.
Study NCT00477321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT 107
Description: 3 dose levels: 3, 10 and 20µg/kg/week.3administrations
Study NCT01449136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibacterial cement
Description: Glass ionomer cement containing 1% each of metronidazole, ciprofloxacin, and cefaclor
Study NCT00705861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as a substitute of SK3530 100mg
Study NCT00705861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK3530
Description: SK3530 100mg
Study NCT00767416 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-559
Description: Cohort 1 (5 to \<24 months): N=80 MEDI-559 at 10\^5 FFU at 0, 2, and 4 months; frozen preparation filled into 0.5 ml luer slip-tip syringes. Each 0.2 ml dose contains 10\^5 FFU MEDI-559 in a sucrose phosphate glutamate buffer.
Study NCT00767416 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cohort 1 (5 to \< 24 months); N = 80 placebo at 0, 2, and 4 months; frozen preparation filled into 0.5 ml luer slip-tip syringes. Each 0.2 ml dose contains sucrose phosphate buffer.
Study NCT03047304 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Trans abdominal sonography
Description: Trans abdominal sonography in order to measure fetal PR interval.
Study NCT04618445 — intervention group
Intervention type: BEHAVIORAL
Intervention: some risk factors that might be correlated with TMD
Description: Fonesca questionnaire
Study NCT00391131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IgNextGen 16%
Description: IgNextGen 16% administered subcutaneously on a weekly basis from visit 1 to 12
Study NCT01274832 — intervention group
Intervention type: DEVICE
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation of STN in Parkinsonian patients
Study NCT00807287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jejunal tube placement using the unguided frictional method
Description: The self-advancing nasal jejunal feeding tube has small alternating cilia-like plastic flaps to help to advance it into the small bowel via peristalsis. The tube is placed in the stomach (50-60 cm mark). Then the tube is left in place for 1 hour to allow the patient's peristalsis to advance the tube by catching its small plastic tabs. Thereafter, the tube is manually advanced 10 cm every hour until the 100 cm mark of length is reached. To improve peristalsis, 10mg metoclopramide i.v. and 200mg erythromycin i.v. 15 minutes before the procedure are administered.
Study NCT00807287 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Jejunal tube placement using the endoscopic method
Description: Jejunal feeding tubes are placed using endoscopy
Study NCT02775695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Treatment with doxycycline hyclate will be administered as an oral agent on an outpatient basis. Patients will receive doxycycline 100 mg twice daily for a period of 8 weeks (56 days). Upon registration (baseline) and at the first, third, and fifth days of doxycycline therapy, patients will be seen to obtain trough serum concentrations for pharmacokinetic studies. Additional serum levels will be checked on days 8, 15, 22 and 29.
Study NCT04062487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mixed Reality technology
Description: combine image with real body
Study NCT04421183 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: draw blood
Description: draw blood from the all of patients
Study NCT02682745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL151
Description: Test drug l : HL151, 1T, single oral administration on an empty stomach, Test drug ll : HL151, 1T, single oral administration after meal
Study NCT03573882 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Voxelotor
Description: 300mg or 500mg Tablet, Oral, With or Without Food
Study NCT04431479 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample
Study NCT04431479 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical chart
Study NCT04431479 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04431479 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study NCT04166006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous DC vaccine
Description: 7-14×106 autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1)
Study NCT04166006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Autologous DC vaccine is followed by IL-2, at a dose of 3 MU, given by subcutaneous injection daily for five days (days 3-7).
Study NCT02682745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TALION tab.
Description: Reference drug: TALION tab, 1T, every 12 hours, oral administration
Study NCT01116102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution
Description: Subcutaneous administration of 150 U HYLENEX, followed by 1000 mL Lactated Ringer's solution
Study NCT01781507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine
Description: Cetirizine is an antihistamine currently indicated for allergic rhinitis
Study NCT01781507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This placebo ( sugar pill) will provide the negative control for this study
Study NCT01992393 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TIME
Description: TIME consists of 12 group sessions in which patients with epilepsy and mental illness will be coached on techniques to help manage their conditions. There will also be four follow-up telephone sessions after the series of group sessions is completed. In addition, approximately half of the participants will participate in qualitative interviews.
Study NCT02277041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute
Study NCT02277041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 600 micro gram of misoprostol which is a prostaglandin E1 will be given per rectum for patients immediately postoperative.
Study NCT00652210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiphoton microscopy
Description: Use of multiphoton microscopy to diagnose cancer
Study NCT03525379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Resveratrol
Description: Subject participation will be approximately 10 weeks in duration. Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.~The schedule for the study is:~Week 0 Screening and randomization Weeks 1-2 Run-in; no treatment Weeks 3-10 Treatment Phase (resveratrol or placebo)
Study NCT03525379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Subject participation will be approximately 10 weeks in duration. Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.~The schedule for the study is:~Week 0 Screening and randomization Weeks 1-2 Run-in; no treatment Weeks 3-10 Treatment Phase (resveratrol or placebo)
Study NCT03525379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.
Study NCT03525379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.
Study NCT04094285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAUERSTOFF
Description: SAUERSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~min. 95.5%, breathing for 30 minutes
Study NCT04094285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STICKSTOFF
Description: STICKSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~88% with 12% oxygen, breathing for 30 minutes
Study NCT03376880 — intervention group
Intervention type: OTHER
Intervention: 1 year follow-up testing
Description: The approach of the study is not in studying the effectiveness of the intervention stimulus, the dose response of diet and exercise, or the rate of weight loss but only the response to 1) weight loss and regular exercise or 2) continued weight gain.
Study NCT00400179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1/Cisplatin
Description: In Arm A, S-1 25 mg/m2 was taken orally two times daily for 21 days followed by a 7-day recovery period. The patient was instructed to have nothing by mouth (NPO 1 hour prior to and 1 hour after S-1 administration. S-1 was taken with approximately 8 ounces of water and prior to cisplatin infusion on Day 1.~Cisplatin 75 mg/m2 was administered as a 1- to 3-hour IV infusion after the morning dose of S-1 on Day 1 of each cycle. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin.
Study NCT00400179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU/cisplatin
Description: In Arm B, 5-FU 1000 mg/m2/24 hours was administered CIV on Days 1 through 5 following cisplatin 100 mg/m2 administered IV as a 1- to 3-hour infusion on Day 1. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin.
Study NCT00693407 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastric capsaicin with heterotopic stimulation/ distraction
Description: The subjects are randomized to swallow either a capsaicin 0.50mg capsule or an identical placebo capsule with 100ml of water If after 15 minutes pain scores do not reach a minimum level of 30, a further double-blinded capsule of the same content will be swallowed with 100ml of water. This is repeated to a maximum of 8 capusles until pain with VAS >30 is reported.
Study NCT00005800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Study NCT00005800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT00005800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT00005800 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Within 6 weeks of completion of neoadjuvant chemotherapy, patients undergo surgery with mastectomy or lumpectomy and axillary lymph node dissection.
Study NCT03389477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib is an oral drug available as capsules (or as liquid suspension). The capsules should be taken with food
Study NCT02678247 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Northwestern University Flexible Sub-Ischial Vacuum Socket
Description: NU-FlexSIV sockets have lower proximal trim lines, do not impinge on the pelvis, are highly flexible so as to allow better comfort during sitting and when muscles move within the socket during activity, and are held securely to the residual limb by suction from a vacuum pump and from compression exerted by the deliberately undersized liner and socket.
Study NCT02678247 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ischial Containment Socket
Description: Ischial Containment (IC) sockets are more rigid and have a narrower medio-lateral dimension than anterior-posterior dimension. The socket encapsulates the ischium, ischial ramus and greater trochanter, limiting hip range of motion and comfort.